Search and analyze individual stocks with comprehensive metrics
Windlas Biotech Ltd
Fundamental Score
Windlas Biotech Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of WINDLAS across key market metrics for learning purposes.
Positive Indicators
10 factors identified
Excellent ROCE Performance (16.96%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.
Attractive Valuation (P/E: 24.62 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.
Strong Revenue Growth (18.93%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential. This indicates business expansion success.
Consistent Growth Track Record (18.24% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model and market opportunity execution over time.
Strong Profit Growth Track Record (30.32% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.
Conservative Debt Levels (D/E: 0.06)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.
Strong Interest Coverage (19.07x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.
Strong Cash Generation (₹78.58 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (61.99%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
1 factors identified
Weak Earnings Growth (2.83% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation. Consider growth catalysts and competitive positioning.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Windlas Biotech Ltd
About WINDLAS
Business Overview
Windlas Biotech Limited, a contract development and manufacturing organization, manufactures and trades in pharmaceutical products in India. The company offers contract manufacturing; customized formulations; contract research and manufacturing services; customized formulation; and regulatory services. It also manufactures tablets, capsules, oral solids, modified-release formulations, chewable and dispersible tablets, customized generics, and complex generics and multi-drug combinations, as well as injectables, including liquid vials, lyophilized vials, and ampoules. In addition, the company offers generic drugs for respiratory, anti-diabetic, gastroenterology, cardiovascular and multivitamin, neuro anti-psychotic, diabetic care, nutraceuticals, nutritional supplement, urology, pain management, and injectable therapies. It also exports generic medicines, health supplements, and custom-branded formulations. Windlas Biotech Limited was incorporated in 2001 and is headquartered in Dehradun, India.
Company Details
Key Leadership
Corporate Events
WINDLAS Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Windlas Biotech Ltd (WINDLAS)?
As of 19 Jan 2026, 10:11 am IST, Windlas Biotech Ltd (WINDLAS) is currently trading at ₹853.10. The stock has a market capitalization of ₹1.66K (Cr).
Is WINDLAS share price Overvalued or Undervalued?
WINDLAS is currently trading at a P/E ratio of 24.62x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Undervalued against its sector peers.
What factors affect the Windlas Biotech Ltd share price?
Key factors influencing WINDLAS's price include its quarterly earnings growth (Sales Growth: 18.93%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Windlas Biotech Ltd a good stock for long-term investment?
Windlas Biotech Ltd shows a 5-year Profit Growth of 30.32% and an ROE of 12.76%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.06 before investing.
How does Windlas Biotech Ltd compare with its industry peers?
Windlas Biotech Ltd competes with major peers in the Pharmaceuticals. Investors should compare WINDLAS's P/E of 24.62x and ROE of 12.76% against the industry averages to determine its competitive standing.
What is the P/E ratio of WINDLAS and what does it mean?
WINDLAS has a P/E ratio of 24.62x compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹25 for every ₹1 of annual earnings.
How is WINDLAS performing according to Bull Run's analysis?
WINDLAS has a Bull Run fundamental score of 62.1/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does WINDLAS belong to?
WINDLAS operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Windlas Biotech Ltd.
What is Return on Equity (ROE) and why is it important for WINDLAS?
WINDLAS has an ROE of 12.76%, which shows decent profitability but room for improvement. Return on Equity measures how efficiently Windlas Biotech Ltd generates profits from shareholders' equity.
How is WINDLAS's debt-to-equity ratio and what does it indicate?
WINDLAS has a debt-to-equity ratio of 0.06, which indicates conservative financing with low financial risk. A ratio below 1.0 generally indicates conservative financing.
What is WINDLAS's dividend yield and is it a good dividend stock?
WINDLAS offers a dividend yield of 0.74%, which means you receive ₹0.74 annual dividend for every ₹100 invested.
How has WINDLAS grown over the past 5 years?
WINDLAS has achieved 5-year growth rates of: Sales Growth 18.24%, Profit Growth 30.32%, and EPS Growth 2.83%.
What is the promoter holding in WINDLAS and why does it matter?
Promoters hold 61.99% of WINDLAS shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is WINDLAS's market capitalization category?
WINDLAS has a market capitalization of ₹1658 crores, placing it in the Small-cap category.
How volatile is WINDLAS stock?
WINDLAS has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for WINDLAS?
WINDLAS has a 52-week high of ₹N/A and low of ₹N/A.
What is WINDLAS's operating profit margin trend?
WINDLAS has a 5-year average Operating Profit Margin (OPM) of 12.13%, indicating the company's operational efficiency.
How is WINDLAS's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of 18.93% and YoY Profit Growth of 13.67%.
What is the institutional holding pattern in WINDLAS?
WINDLAS has FII holding of 1.11% and DII holding of 11.44%. Significant institutional holding often suggests professional confidence in the stock.